.Attribute Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of people along with HER2+ state-of-the-art bosom cancer cells and active or even steady brain metastases showed regular intracranial activity and wide spread effectiveness of T-DXd.